This suggests, at least anecdotally, that ERBB2 activating mutations do not cause intrinsic endocrine therapy resistance, with high on-AI-treatment Ki67 values that were noted when studying HER2 amplified ER+ tumours in the neoadjuvant endocrine setting29. Here, ESR1 is linked to neoplasm.